Related Experiment Video
Updated: Jun 3, 2026

Murine Renal Transplantation Procedure
Published on: July 10, 2009
[Pneumocystis pneumonia in a renal transplant recipient]
Soykan Özkoç1, Tonay İnceboz, Aykut Sıfıl
1Dokuz Eylül Üniversitesi Tıp Fakültesi, Parazitoloji Anabilim Dalı, İzmir, Türkiye. soykan.ozkoc@deu.edu.tr
Abstract:
Pneumocystis pneumonia (PCP) is an opportunistic infection caused by Pneumocystis jirovecii (P. jirovecii) in humans. We reported a 23 year-old male patient who developed pneumonia after renal transplantation. P. jirovecii cysts and trophozoites were detected in bronchoalveolar lavage (BAL) samples of the patient by Giemsa, methenamine-silver and Toluidine-O staining. The patient, who was diagnosed as PCP, was discharged as he recovered by 21 days trimethoprim-sulfamethoxazole (TMP-SMX) therapy. This case, who developed PCP even though he had received prophylaxis after transplantation, was reported to emphasize the importance of the agent in immunocompromised patients.
Insights
Pneumocystis pneumonia (PCP), an opportunistic infection, can occur even with prophylaxis in immunocompromised patients. This case highlights the importance of vigilant monitoring and treatment for Pneumocystis jirovecii in transplant recipients.
Area of Science:
- Medicine
- Infectious Diseases
- Transplantation Immunology
Background:
- Pneumocystis pneumonia (PCP) is a severe opportunistic infection caused by Pneumocystis jirovecii.
- Renal transplant recipients are particularly vulnerable to opportunistic infections due to immunosuppression.
Observation:
- A 23-year-old male renal transplant recipient developed pneumonia.
- Pneumocystis jirovecii was identified in bronchoalveolar lavage samples using Giemsa, methenamine-silver, and Toluidine-O staining.
- The patient had been receiving prophylaxis for PCP post-transplantation.
Findings:
- The patient was diagnosed with Pneumocystis pneumonia.
- Successful treatment was achieved with 21 days of trimethoprim-sulfamethoxazole (TMP-SMX) therapy.
- Recovery was observed within 21 days of treatment initiation.
Implications:
- This case underscores the importance of vigilant monitoring for PCP in immunocompromised patients, even those on prophylaxis.
- Early detection and appropriate treatment are crucial for managing PCP in transplant recipients.
- The study emphasizes the persistent risk of P. jirovecii infection in immunocompromised populations.
More Related Videos
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction
Continuous Renal Replacement Therapy

